ShRNA silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic cancer

Cancer Letters

Volumn 316, Issue 2, 2012, Pages 178-186

  Zhou, Wei ^a   Wang, Li ^a   Gou, Shan miao ^a   Wang, Tong ling ^a   Zhang, Meng ^a   Liu, Tao ^a   Wang, Chun you ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

GSK 3 ; Molecular targeted therapy; Pancreatic neoplasia; RNA interference

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; PROTEIN BCL 2; SHORT HAIRPIN RNA; VASCULOTROPIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84855991351     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.10.033     Document Type: Article

References (39)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010, CA. Cancer J. Clin. 2010, 60:277-300.
2. Rayasam G.V., Tulasi V.K., Sodhi R., Davis J.A., Ray A. Glycogen synthase kinase 3: more than a namesake. Br. J. Pharmacol. 2009, 156:885-898.
3. Doble B., Woodgett J. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 2003, 116:1175-1186.
4. Patel S., Doble B., Woodgett J.R. Glycogen synthase kinase-3 in insulin and Wnt signalling: a double-edged sword?. Biochem. Soc. Trans. 2004, 32:803-808.
5. Patel M.P., Masood A., Patel P.S., Chanan-Khan A.A. Targeting the Bcl-2. Curr. Opin. Oncol. 2009, 21:516-523.
6. Bachelder R.E., Yoon S.O., Franci C., de Herreros A.G., Mercurio A.M. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J. Cell. Biol. 2005, 168:29-33.
7. Wang Y., Lam J.B., Lam K.S., Liu J., Lam M.C., Hoo R.L., Wu D., Cooper G.J., Xu A. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res. 2006, 66:11462-11470.
8. Ghosh J.C., Altieri D.C. Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells. Clin. Cancer Res. 2005, 11:4580-4588.
9. Zhou Y., Uddin S., Zimmerman T., Kang J.A., Ulaszek J., Wickrema A. Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leuk. Lymphoma 2008, 49:1945-1953.
10. Luo J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett. 2009, 273:194-200.
11. Gao X., Zhang H., Takahashi T., Hsieh J., Liao J., Steinberg G.K., Zhao H. The Akt signaling pathway contributes to postconditioning's protection against stroke; the protection is associated with the MAPK and PKC pathways. J. Neurochem. 2008, 105:943-955.
12. Hartigan J.A., Xiong W.C., Johnson G.V. Glycogen synthase kinase 3beta is tyrosine phosphorylated by PYK2. Biochem. Biophys. Res. Commun. 2001, 284:485-489.
13. Takahashi-Yanaga F., Shiraishi F., Hirata M., Miwa Y., Morimoto S., Sasaguri T. Glycogen synthase kinase-3beta is tyrosine-phosphorylated by MEK1 in human skin fibroblasts. Biochem. Biophys. Res. Commun. 2004, 316:411-415.
14. Lesort M., Jope R.S., Johnson G.V. Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. J. Neurochem. 1999, 72:576-584.
15. Mai W., Kawakami K., Shakoori A., Kyo S., Miyashita K., Yokoi K., Jin M., Shimasaki T., Motoo Y., Minamoto T. Deregulated GSK3{beta} sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase. Clin. Cancer Res. 2009, 15:6810-6819.
16. Shakoori A., Ougolkov A., Yu Z., Zhang B., Modarressi M., Billadeau D., Mai M., Takahashi Y., Minamoto T. Deregulated GSK3 [beta] activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem. Biophys. Res. Commun. 2005, 334:1365-1373.
17. Leis H., Segrelles C., Ruiz S., Santos M., Paramio J.M. Expression, localization, and activity of glycogen synthase kinase 3beta during mouse skin tumorigenesis. Mol. Carcinog. 2002, 35:180-185.
18. Greene F.L. TNM staging for malignancies of the digestive tract: 2003 changes and beyond. Semin. Surg. Oncol. 2003, 21:23-29.
19. Cho Y.J., Kim J.H., Yoon J., Cho S.J., Ko Y.S., Park J.W., Lee H.S., Lee H.E., Kim W.H., Lee B.L. Constitutive activation of glycogen synthase kinase-3beta correlates with better prognosis and cyclin-dependent kinase inhibitors in human gastric cancer. BMC Gastroenterol. 2010, 10:91.
20. Li W., Ding F., Zhang L., Liu Z., Wu Y., Luo A., Wu M., Wang M., Zhan Q. Overexpression of stefin A in human esophageal squamous cell carcinoma cells inhibits tumor cell growth, angiogenesis, invasion, and metastasis. Clin. Cancer Res. 2005, 11:8753-8762.
21. Ougolkov A.V., Fernandez-Zapico M.E., Bilim V.N., Smyrk T.C., Chari S.T., Billadeau D.D. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin. Cancer Res. 2006, 12:5074-5081.
22. Ougolkov A.V., Fernandez-Zapico M.E., Savoy D.N., Urrutia R.A., Billadeau D.D. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 2005, 65:2076-2081.
23. Mishra R. Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol. Cancer 2010, 9:144.
24. Cao Q., Lu X., Feng Y.J. Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res. 2006, 16:671-677.
25. Zhang J., Koenig A., Harrison A., Ugolkov A., Fernandez-Zapico M., Couch F., Billadeau D. Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer. Oncogene 2011, 30:3705-3715.
26. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005, 69(Suppl. 3):11-16.
27. Skurk C., Maatz H., Rocnik E., Bialik A., Force T., Walsh K. Glycogen-synthase Kinase3beta/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells. Circ. Res. 2005, 96:308-318.
28. Kim H.S., Skurk C., Thomas S.R., Bialik A., Suhara T., Kureishi Y., Birnbaum M., Keaney J.F., Walsh K. Regulation of angiogenesis by glycogen synthase kinase-3beta. J Biol. Chem. 2002, 277:41888-41896.
29. Semenza G.L. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin. Cancer Biol. 2009, 19:12-16.
30. Dungwa J.V., Hunt L.P., Ramani P. Overexpression of carbonic anhydrase and HIF-1alpha in Wilms tumours. BMC Cancer 2011, 11:390.
31. Liu L.Z., Li C., Chen Q., Jing Y., Carpenter R., Jiang Y., Kung H.F., Lai L., Jiang B.H. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS One 2011, 6:e19139.
32. Maynard M.A., Ohh M. The role of hypoxia-inducible factors in cancer. Cell Mol. Life Sci. 2007, 64:2170-2180.
33. Flugel D., Gorlach A., Michiels C., Kietzmann T. Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner. Mol. Cell Biol. 2007, 27:3253-3265.
34. Ulahannan S.V., Brahmer J.R. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest. 2011, 29:325-337.
35. Kindler H.L., Niedzwiecki D., Hollis D., Sutherland S., Schrag D., Hurwitz H., Innocenti F., Mulcahy M.F., O'Reilly E., Wozniak T.F., Picus J., Bhargava P., Mayer R.J., Schilsky R.L., Goldberg R.M. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 2010, 28:3617-3622.
36. Friess H., Langrehr J.M., Oettle H., Raedle J., Niedergethmann M., Dittrich C., Hossfeld D.K., Stoger H., Neyns B., Herzog P., Piedbois P., Dobrowolski F., Scheithauer W., Hawkins R., Katz F., Balcke P., Vermorken J., van Belle S., Davidson N., Esteve A.A., Castellano D., Kleeff J., Tempia-Caliera A.A., Kovar A., Nippgen J. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 2006, 6:285.
37. Spano J.P., Chodkiewicz C., Maurel J., Wong R., Wasan H., Barone C., Letourneau R., Bajetta E., Pithavala Y., Bycott P., Trask P., Liau K., Ricart A.D., Kim S., Rixe O. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008, 371:2101-2108.
38. Kindler H.L., Wroblewski K., Wallace J.A., Hall M.J., Locker G., Nattam S., Agamah E., Stadler W.M., Vokes E.E. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest. New Drugs 2010, 28:28.
39. Bilim V., Ougolkov A., Yuuki K., Naito S., Kawazoe H., Muto A., Oya M., Billadeau D., Motoyama T., Tomita Y. Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br. J. Cancer 2009, 101:2005-2014.